Scarica l'app Stockscreener
44.50
0.80%
-0.36
Pre-mercato:
44.25
-0.25
-0.56%
Uniqure Nv Borsa (QURE) Ultime notizie
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players - NeurologyLive
Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily
QURE stock gains as uniQure moves closer to FDA review for Huntington’s gene therapy - AD HOC NEWS
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval - finance.yahoo.com
uniQure Submits BLA and MAA for AMT-130 Gene Therapy in Huntington's Disease - BioPharm International
QURE Submits Application for Gene Therapy for Huntington's Disease - theglobeandmail.com
QURE Reinstated by William Blair -- Rating Set to Outperform - GuruFocus
Why is Uniqure NV stock gaining today? - Investing.com
uniQure seeks FDA accelerated nod for gene therapy (QURE) - Seeking Alpha
uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says - Benzinga
uniQure seeks US approval for Huntington's gene therapy after FDA reversal - Reuters
Why is Uniqure NV stock gaining today? By Investing.com - Investing.com Canada
QURE Looks 505.1% Overvalued on GF Value™ - GuruFocus
UniQure Submits BLA for AMT-130 in Huntington's Disease - marketscreener.com
uniQure submits BLA to FDA and MAA to MHRA for AMT-130 in Huntington’s disease - TradingView
uniQure Announces Submission of Biologics License - GlobeNewswire
uniQure sets July 29 webcast after Q2 financial results - Stock Titan
Uniqure (QURE) Financials FY2025: Revenue $16.1M, Net Loss $199.0M | Income Statement & Balance Sheet - Stock Titan
Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report? - Yahoo Finance
Price to sales forward of uniQure N.V. – NASDAQ:QURE - TradingView
RTW INVESTMENTS, LP Buys uniQure NV (QURE) -- Shares Look 531% O - GuruFocus
uniQure N.V. - Reuters
Royal Bank of Canada Increases Stock Position in uniQure N.V. $QURE - MarketBeat
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure (QURE) Advances 3.31% as Gene Therapy Optimism ReturnsDividend Growth Stocks - Vinanet
Responsive Playbooks and the QURE Inflection - Stock Traders Daily
uniQure (NASDAQ:QURE) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Susquehanna entities (QURE) disclose 3.34M-share, 4.8% position in uniQure - Stock Titan
RTW Investments (QURE) discloses 3.94M-share beneficial stake in uniQure N.V. - Stock Titan
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $71 - Moomoo
uniQure (QURE) Q2 2026 Earnings Call Transcript - AOL.com
Hennion & Walsh Asset Management Inc. Increases Holdings in uniQure N.V. $QURE - MarketBeat
Assenagon Asset Management S.A. Has $23.65 Million Position in uniQure N.V. $QURE - MarketBeat
Why uniQure (QURE) Is Up 6.4% After FDA Alignment On Accelerated AMT-130 Approval Path - simplywall.st
Uniqure NV (QURE) Stock News Today - TradingKey
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
UniQure N.V. (QURE) Stock Analysis: Exploring A 53.35% Potential Upside In Gene Therapy - DirectorsTalk Interviews
uniQure N.V. (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
QURE|Uniqure NV|Price:44.206|Chg%:-0.034 - TradingKey
Weekly Recap: AMT-130 readout and Wells Fargo raises QURE target to $75 - TradingView
Militia Capital Management LLC Invests $1.54 Million in uniQure N.V. $QURE - MarketBeat
uniQure N.V. (QURE) Stock Analysis: Assessing Upside Potential and Analyst Confidence in Biotech Innovator - DirectorsTalk Interviews
uniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter Course (NASDAQ:QURE) - Seeking Alpha
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y - TradingView
Uniqure NV earnings missed by $0.38, revenue topped estimates - Investing.com Nigeria
uniQure N.V. 2026: Revenue $5.84M, EPS ($1.22) — 10-Q Summary - TradingView
UniQure: Q2 Earnings Snapshot - 10tv.com
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update - GlobeNewswire
Uniqure NV reports results for the quarter ended June 30Earnings Summary - TradingView
uniQure N.V. Revenue Breakdown – NASDAQ:QURE - TradingView
uniQure earnings in focus as AMT-130 gene therapy BLA looms By Investing.com - Investing.com Australia
uniQure earnings in focus as AMT-130 gene therapy BLA looms - Investing.com
Uniqure NV (QURE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Uniqure NV (QURE) Income Statement - TradingKey
Uniqure NV (QURE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Uniqure NV (QURE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):